Hosted on MSN1mon
FDA approves J&J's patented psychedelic esketamine for depression without requiring you take other antidepressants with it
On Tuesday, the US Food and Drug Administration (FDA) approved Johnson & Johnson's hallucinogenic drug esketamine (brand name Spravato) nasal spray as a "monotherapy" treatment for major ...
Johnson & Johnson ketamine-derived nasal spray gets FDA approval for depression, but JNJ stock dips on earnings
Spravato is now the first stand-alone therapy for treatment-resistant depression, for patients who haven't responded to oral antidepressants.
FDA approves first-of-its-kind nasal spray for severe depression
Johnson & Johnson has announced the FDA’s approval of a first-of-its-kind, esketamine nasal spray called Spravato for the standalone treatment of major depressive disorder (MDD), PTSD, and similar ...
Seeking Alpha1mon
J&J wins label expansion for depression therapy Spravato
Johnson & Johnson (NYSE:JNJ) announced Tuesday that the U.S. FDA approved a supplemental New Drug Application for its depression therapy Spravato (esketamine), expanding its use as a single agent ...
Seeking Alpha29d
Why Johnson & Johnson's Strong Buy Rating Is Justified (Rating Upgrade)
However, Johnson & Johnson has a 'savior' in its neuroscience portfolio, namely Spravato (esketamine), which is the NMDA receptor antagonist. Moreover, on January 21, 2025, the FDA approved ...
Hosted on MSN1mon
FDA-Approved Nasal Spray For Depression Is First Of Its Kind
The FDA first approved the Johnson & Johnson drug, called Spravato (esketamine), for some cases of depression in 2019, but it was only allowed to be prescribed alongside an oral antidepressant.